

Efficiently Measuring Efficiency: Is Judgment the Correct Path

Howard Beckman, MD Medical Director RIPA Rochester, NY



Cost Efficiency: Competition and Judgment

- Urgent need for Cost Efficiency
- Current in vogue models involve public reporting, tiering, limiting panels
- Inherent in these models are competition and judgment



Cost Efficiency: Competition and Judgment

The core measurement for cost efficiency is the efficiency index – a comparison of one practitioner's case-mix adjusted costs to peers Based on responsible or total costs Can be age and sex adjusted Cost variables such as facility or pharmacy costs can be flattened to focus attention on what can be changed




Efficiency Indexes – Pros and Cons

- + Based on comparisons with peers or benchmarked group
- + Comparisons encourage a response
- Case mix adjusted through episode grouping software
- Judgmental evaluates doctor, not behaviors
- Reductionistic assumes generally + or -
- Limited actionability costly to get to action
- Not adequately severity adjusted

Internal Medicine and Family Practice Number of Measures



A Doctor is 25% Above or 25% Below Peers In Specialty



Each point is a doctor

Methodological Problems with Efficiency Indexes

- Practitioners are generally efficient at some things but not others (82% in the middle)
- Few distinctly better (11%) and worse (8%) overall physicians
- Focusing on the practitioner creates defensiveness, humiliation and the creation of committed enemies



Conclusions

- For cost efficiency, the physician is not the most effective unit of analysis
- Efficiency indexes are too indirect and personal to be actionable
- Fear as the motivational tool does not promote collaboration
- Focusing on appropriately selected behaviors is a more logical strategy



The Next Generation: Adding Overuse and Underuse Measures to the Quality Paradigm



Childhood Immunization Rates 2003 Among pediatricians with at least 20 eligible



Internists HTN Rx Costs per Episode

1/1/2002-12/31/2003 data load

\$900	
	•
\$800	•
\$700	•••
	••••
\$600	••••
	•••••
\$500	

\$400	
	······································
\$300	
	·····
\$200	


\$100	


\$0	

Advisory Committee members show in red.

Arthroscopic Debridement 29877 Rates

Among all patients, 2002-2003, Selected Orthopecists






What Is Needed




- By condition, find the **local-regional** variation in specific services
- Understand if the variation represents overuse or misuse – have the quality conversation
- Find overuse-misuse reduction opportunities for a whole specialty = find best practices
- Create a series of measures based on reducing overuse or underuse offering interventions based on best practices
- Reduce costs while improving quality not by chance, but by DESIGN

MPPT[™] Analysis of Hypertension*


(ETG 0281, Benign HTN w/o comorbidity, among 260 internists)




Cost Variation – All in Pharmacy



Pharmacy Analysis: Best Practice is Quintile 1




Removing Benign Skin Growths



Provided by FMA

Hypothetical Costs for Illustration Only

Drilling Down on Procedures



Creating a Blueprint for Change

Provided by Focused Medical Analytics

ľ	<u>E</u> ile <u>E</u> di	it <u>V</u> iew	Insert	F <u>o</u> rmat	<u>T</u> ools [<u>D</u> ata <u>W</u>	jindow <u>H</u>	elp									Type a qu	estion for	help 🚽 👻	- 8	
_	A100	•	f _x																		
	A	В	C	D	E	F	G	H	I	J	K	L	M	N	0	Р	Q	R	S	-	
	An M	CO's	Medi	cal Ma	inage	emen	t Blue	print		Confi	dent	al									
	Key:	C I	tion. ETG			Detabase	ed on dates:	10000 510	0.05	0	2000 F		dical Analy	No. 110	AU -: -L.						
-		REI Costs		Number % Spec REI		Data base	ed on dates:	1/2003 - 5/2	:005	Patent pe		cusea me	dical Analy	ICCS, LLC.	All rights	s reservea	•				
_		Findings									_										
+		Strategy Id	Pas																		
_		Potential s					cians practic	ed like				ete estimates									
+		% of specia	alty potentia	savings		lower str	atum			Figures in b	ack: comp	leted estimat	ies								
1	Internal Medicine			Total \$\$ in t				Percent o		32.5%		Total REI \$	65:	#######							
		Benign hypertension, wło comorbidity, 0281			Non-insulin dependent diabetes, with comorbidity, 0029			Inflammation of the esophagus, w/o surgery, 0433			Insulin dependent diabetes, with comorbidity, 0027			Acute sinusitis, 0333			Dermatitis ¹¹¹			Acute brond comorbidity, a	
	#######		6.2%	########	2	5.9%	#######	3	3.8%	########	4				2.6%		6	2.4%		iuity.	
	Q1 consiste																				
+	Q5 Rxs CCI	B, AHB, co	mbos																		
_	#######																				
+	Family Practice		Total \$\$ in top ETGs: ######			Percent of REI \$\$:			30.8% Total REI S			\$\$: ####### Tonsillitis, adenoiditis or									
		Non-insulin dependent diabetes, with comorbidity, 0029			Benign hypertension, w/o comorbidity, 0281		Acute sinusitis, 0333			Inflammation of the esophagus, w/o surgery, 0433				jitis, adeno 0331		Dermatitis ¹¹¹			Minor	depre	
	#######	1	4.3%	#######	2	4.0%		3		#######	4	3.3%	#######		3.3%		6		######		
_																					
-																					
																topical ste	roid costs				
	Pediatric	s		Total \$\$ in t	op ETGs:	*****		Percent o	f REI \$\$:	44.8%		Total REI \$	66:	#######							
	Tonsillitis, adenoiditis or pharyngitis, w/o surgery,		Otitis media, wło surgery,			Uncomplicated neonatal			Attention Deficit Disorder,						Other major neonatal disorders, perinatal origin,						
╈	#######	0331	11.9%	########	0329 2	9.0%		agement, (3	0780 5.7%	#######	<u>0101</u> 4	3.9%	D: ########	ermatitis 5	3.4%	#######	0786 6	3 3%	Acute #######	sinu	
t			11.576		-	1 0.070			0.170			0.070			0.470			0.070			
1																					
				T-1-1 00 - 1	FTO			Develoption	(DEL 00-			T-I-I DEL	n							_	
+	Ear, Nose, and Throat		Total \$\$ in t	op ETGS:	######		Percent o	(FRE) \$\$	63.6%		Total REI \$	рф: 	#######								
;		nsillitis, adenoiditis or aryngitis, with surgery, 0330		Chronic sinusitis, with surgery, 0334		Otitis media, with minor surgery, 0328		Chronic sinusitis, wło surgery, 0335			Otitis media, wło surgery, 0329			Tonsillitis, adenoiditis or pharyngitis, wło surgery, 0331			ENT cong acquired ano surgery				
Т	######	1	18.2%	#######	2	9.7%		3		\$854,013	4	6.6%	\$705,534		5.5%	\$571,198	6	4.4%	######		
T																					



Conclusions

- Focus on reducing overuse instead of relying on efficiency indexes
- Find specific action items to improve value
- Direct attention to meaningful action items to engage practitioners as partners
- Change physician behavior through incentives, avoid "punishing bad docs" as primary motivational strategy